Jazz Pharmaceuticals (JAZZ) Income from Continuing Operations (2010 - 2026)
Jazz Pharmaceuticals' quarterly Income from Continuing Operations came in at 293100000.0 in Q1 2026, up 418.59% year-on-year from 56518968.77 in Q1 2025, and up 44.05% quarter-over-quarter from 203471000.0 in Q4 2025.
Jazz Pharmaceuticals has reported Income from Continuing Operations for 17 years, with the latest figure at 293100000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 418.59% year-over-year to 293100000.0; the trailing twelve-month figure through Mar 2026 stood at 29676000.0 (down 93.86% YoY), and the FY2025 full-year result was 355459000.0, down 163.27% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 293100000.0, up from 203471000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 293100000.0 in Q1 2026, with the low at 718354000.0 in Q2 2025.
- Average Income from Continuing Operations over 5 years is 41362352.94, with a median of 94638000.0 recorded in 2023.
- Year-over-year, Income from Continuing Operations sank 641.8% in 2022 and surged 1109.01% in 2023.
- Tracing JAZZ's Income from Continuing Operations over 5 years: stood at 239951000.0 in 2022, then jumped by 139.44% to 94638000.0 in 2023, then surged by 101.96% to 191131000.0 in 2024, then gained by 6.46% to 203471000.0 in 2025, then soared by 44.05% to 293100000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 293100000.0 (Q1 2026), 203471000.0 (Q4 2025), and 251459000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn | 293.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 293.10 Mn |
| Dec 31, 2025 | 203.47 Mn |
| Sep 30, 2025 | 251.46 Mn |
| Jun 30, 2025 | -718.35 Mn |
| Mar 31, 2025 | -92.00 Mn |
| Dec 31, 2024 | 191.13 Mn |
| Sep 30, 2024 | 215.34 Mn |
| Jun 30, 2024 | 168.58 Mn |
| Mar 31, 2024 | -13.30 Mn |
| Dec 31, 2023 | 94.64 Mn |
| Sep 30, 2023 | 146.72 Mn |
| Jun 30, 2023 | 106.08 Mn |
| Mar 31, 2023 | 70.43 Mn |
| Dec 31, 2022 | -239.95 Mn |
| Sep 30, 2022 | -17.13 Mn |
| Jun 30, 2022 | 37.13 Mn |
| Mar 31, 2022 | 5.83 Mn |
| Dec 31, 2021 | -32.35 Mn |
| Sep 30, 2021 | -49.58 Mn |
| Jun 30, 2021 | -364.66 Mn |
| Mar 31, 2021 | 117.69 Mn |
| Dec 31, 2020 | 134.04 Mn |
| Sep 30, 2020 | 148.86 Mn |
| Jun 30, 2020 | 116.65 Mn |
| Mar 31, 2020 | -158.00 Mn |
| Dec 31, 2019 | 75.29 Mn |
| Sep 30, 2019 | 103.31 Mn |
| Jun 30, 2019 | 262.77 Mn |
| Mar 31, 2019 | 86.11 Mn |
| Dec 31, 2018 | 160.31 Mn |
| Sep 30, 2018 | 149.80 Mn |
| Jun 30, 2018 | 92.91 Mn |
| Mar 31, 2018 | 46.33 Mn |
| Dec 31, 2017 | 232.58 Mn |
| Sep 30, 2017 | 63.80 Mn |
| Jun 30, 2017 | 105.81 Mn |
| Mar 31, 2017 | 86.67 Mn |
| Dec 31, 2016 | 116.97 Mn |
| Sep 30, 2016 | 89.93 Mn |
| Jun 30, 2016 | 114.50 Mn |
| Mar 31, 2016 | 75.81 Mn |
| Dec 31, 2015 | 82.76 Mn |
| Sep 30, 2015 | 87.96 Mn |
| Jun 30, 2015 | 88.11 Mn |
| Mar 31, 2015 | 70.70 Mn |
| Dec 31, 2014 | 81.61 Mn |
| Sep 30, 2014 | 25.77 Mn |
| Jun 30, 2014 | 43.59 Mn |
| Mar 31, 2014 | -93.64 Mn |
| Sep 30, 2013 | 75.41 Mn |
| Jun 30, 2013 | 42.19 Mn |
| Mar 31, 2013 | 43.43 Mn |
| Dec 31, 2012 | 166.21 Mn |
| Sep 30, 2012 | 33.60 Mn |
| Jun 30, 2012 | 31.11 Mn |
| Mar 31, 2012 | 30.24 Mn |
| Dec 31, 2011 | 37.47 Mn |
| Sep 30, 2011 | 32.48 Mn |
| Jun 30, 2011 | 33.20 Mn |
| Mar 31, 2011 | 21.83 Mn |
| Dec 31, 2010 | 13.38 Mn |
| Sep 30, 2010 | 13.24 Mn |
| Jun 30, 2010 | 10.33 Mn |